Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Cancer Biol Ther ; 8(18): 1719-21, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19633420

ABSTRACT

BACKGROUND: Although the prognosis for malignant gliomas is normally dismal, it's not infrequent in neurooncologist's experience to find cases with unusually prolonged survival. In order to understand what factors influence survival of high grade glioma patients, a cohort of 196 high (III-IV) grade glioma patients was investigated for possible association between (1) survival and age at diagnosis; (2) survival and micronuclei in tumor tissue; (3) survival and gender; (4) micronuclei in tumor tissue and age at diagnosis. RESULTS: Patients diagnosed at an older age (>64 years) had a significantly higher hazard as compared to younger patients (

Subject(s)
Glioma/diagnosis , Glioma/genetics , Age Factors , Aged , Chromosomal Instability , Cohort Studies , Female , Humans , Italy , Kaplan-Meier Estimate , Male , Micronucleus Tests/statistics & numerical data , Middle Aged , Prognosis , Proportional Hazards Models
2.
Mol Cancer Res ; 7(3): 383-92, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19276180

ABSTRACT

It has been reported that cancer stem cells may contribute to glioma radioresistance through preferential activation of the DNA damage checkpoint response and an increase in DNA repair capacity. We have examined DNA repair in five stem and nonstem glioma cell lines. The population doubling time was significantly increased in stem compared with nonstem cells, and enhanced activation of Chk1 and Chk2 kinases was observed in untreated CD133(+) compared with CD133(-) cells. Neither DNA base excision or single-strand break repair nor resolution of pH2AX nuclear foci were increased in CD133(+) compared with CD133(-) cells. We conclude that glioma stem cells display elongated cell cycle and enhanced basal activation of checkpoint proteins that might contribute to their radioresistance, whereas enhanced DNA repair is not a common feature of these cells.


Subject(s)
Brain Neoplasms/genetics , DNA Repair , Glioblastoma/genetics , Neoplastic Stem Cells/physiology , AC133 Antigen , Animals , Antigens, CD/biosynthesis , Antigens, CD/genetics , Apoptosis/physiology , Brain Neoplasms/metabolism , Brain Neoplasms/pathology , Cell Line, Tumor , Checkpoint Kinase 1 , Checkpoint Kinase 2 , DNA Damage , Enzyme Activation , Glioblastoma/metabolism , Glioblastoma/pathology , Glycoproteins/biosynthesis , Glycoproteins/genetics , Humans , Karyotyping , Male , Mice , Mice, Inbred NOD , Mice, SCID , Neoplastic Stem Cells/metabolism , Neoplastic Stem Cells/pathology , Peptides/genetics , Protein Kinases/metabolism , Protein Serine-Threonine Kinases/metabolism
3.
BMC Cancer ; 9: 59, 2009 Feb 18.
Article in English | MEDLINE | ID: mdl-19226458

ABSTRACT

BACKGROUND: The COOH terminal peptide of Pro-collagen type I (PICP, also called C3) is chemotactic for endothelial melanoma and breast cancer cells. PICP induces the expression of Metalloproteinases-2 and -9, of Vascular endothelial growth factor and of the chemokine CXCL-12 receptor CXCR4 in MDA MB231 breast carcinoma cells in vitro. METHODS: We used a model of xenografts in BalbC/nude mice obtaining tumors by implanting in contro-lateral subcutaneous positions MDA MB231 cells added or not with purified PICP and studied the earlier phases of tumor development, up to 48 days from implant, by histology, immunostain and in situ hybridization. RESULTS: Addition of PICP promotes rapid vascularization of the tumors while does not affect mitotic and apoptotic indexes and overall tumor growth. PICP-treated, relative to control tumors, show up-modulation of Vascular endothelial factor, Metalloproteinase-9 and CXCR4, all tumor prognostic genes; they also show down-modulation of the endogenous Metalloproteinase inhibitor, reversion-inducing-cysteine-rich protein with kazal motifs, and a different pattern of modulation of Tissue Inhibitor of Metalloproteinase-2. These changes occur in absence of detectable expression of CXCL-12, up to 38 days, in control and treated tumors. CONCLUSION: PICP has an early promoting effect in the acquisition by the tumors of prometastatic phenotype. PICP may be play a relevant role in the productive interactions between stroma and tumor cells by predisposing the tumor cells to respond to the proliferation stimuli ensuing the activation of signaling by engagement of CXCR4 by cytokines and by fostering their extravasion, due to the induction of increased vascular development.


Subject(s)
Breast Neoplasms/blood supply , Breast Neoplasms/pathology , Peptide Fragments/pharmacology , Procollagen/pharmacology , Animals , Breast Neoplasms/genetics , Breast Neoplasms/metabolism , Chemokine CXCL12/biosynthesis , Chemokine CXCL12/genetics , Female , Gene Expression/drug effects , Humans , In Situ Hybridization , Matrix Metalloproteinase 2/biosynthesis , Matrix Metalloproteinase 2/genetics , Matrix Metalloproteinase 9/biosynthesis , Matrix Metalloproteinase 9/genetics , Mice , Mice, Inbred BALB C , Mice, Nude , Neoplasm Metastasis , Neovascularization, Pathologic/enzymology , Neovascularization, Pathologic/genetics , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , RNA, Messenger/biosynthesis , RNA, Messenger/genetics , Receptors, CXCR4/biosynthesis , Receptors, CXCR4/genetics , Transplantation, Heterologous , Vascular Endothelial Growth Factor A/biosynthesis , Vascular Endothelial Growth Factor A/genetics
4.
Free Radic Biol Med ; 42(12): 1807-17, 2007 Jun 15.
Article in English | MEDLINE | ID: mdl-17512460

ABSTRACT

Repair of the oxidized purine 8-oxo-7,8-dihydroguanine (8-oxoGua) is inefficient in cells belonging to the B complementation group of Cockayne syndrome (CS-B), a developmental and neurological disorder characterized by defective transcription-coupled repair. We show here that cells belonging to the A complementation group (CS-A) are also defective in repair of 8-oxoGua and we demonstrate that expression of the Escherichia coli formamidopyrimidine DNA glycosylase (FPG) completely corrects the repair deficiency in both CS-A and CS-B cells. Phenotypically, CS-A cells are normally sensitive to toxicity and micronuclei induced by the oxidizing agent potassium bromate. CS-B cells display sensitivity to elevated concentrations of potassium bromate but this is not compensated by FPG expression, suggesting toxicity of lesions that are not FPG substrates. The data indicate that 8-oxoGua is not a major toxic and clastogenic lesion in CS cells.


Subject(s)
Cockayne Syndrome/genetics , DNA Damage , DNA Repair , DNA-Formamidopyrimidine Glycosylase/metabolism , Escherichia coli/enzymology , Genetic Complementation Test , Adolescent , Adult , Aged , Aged, 80 and over , Bromates/pharmacology , Carcinogens/pharmacology , Cell Survival/drug effects , Cells, Cultured/drug effects , Colony-Forming Units Assay , DNA-Formamidopyrimidine Glycosylase/genetics , Female , Fibroblasts/drug effects , Genetic Vectors , Humans , Kidney/metabolism , Kidney/pathology , Male , Micronucleus Tests , Transcription, Genetic , Urinary Bladder Neoplasms/metabolism , Urinary Bladder Neoplasms/pathology
5.
J Biol Chem ; 278(6): 3639-47, 2003 Feb 07.
Article in English | MEDLINE | ID: mdl-12441353

ABSTRACT

Breast and prostatic carcinomas, melanoma, and endothelial cell lines are chemoattracted by medium conditioned by mature osteoblasts. The chemoattractant for endothelial cells was identified with C3, carboxyl-terminal trimer of pro-collagen type I. We report that C3 induces directional migration and proliferation, the expression of tissue inhibitor of metalloproteinases-2, pro-metalloproteinase-2 and -9, and their activation in MDA MB231 cells, without changing the expression of tissue inhibitor of metalloproteinases-1 and of metalloproteinase-14. Antiserum against metalloproteinase-2 or -9 or -14, tissue inhibitor of metalloproteinases-1, or GM6001 inhibits the C3-induced migration. Urokinase and its receptor are detected and unchanged upon exposure to C3. The antibody against urokinase or addition of plasminogen activator inhibitor inhibits migration. Blocking antibodies to integrins alpha(2), alpha(6), beta(1), and beta(3) inhibit chemotaxis and do not change urokinase and urokinase receptor expression. Blockage of alpha(2), beta(1), and beta(3) integrins affect differently the induction by C3 of pro-metalloproteinase-2 and -9 and of tissue inhibitor of metalloproteinases-2. Chemotaxis to C3 is also inhibited by genistein, by pertussis toxin, which also inhibits C3-induced pro-metalloproteinase -2 and -9, but not urokinase expression. Wortmannin partially inhibits C3-induced cell migration. Other, but not all, breast carcinoma lines tested responded to C3 with migration and pro-metalloproteinase-2 induction. Presently C3 is the only agent known to induce migration specifically of both endothelial and breast carcinoma cells. The mitogenic and motogenic role of C3 in vitro might prefigure a role in in vivo carcinogenesis and in the establishment of metastasis.


Subject(s)
Breast Neoplasms/enzymology , Cell Movement/physiology , Metalloendopeptidases/metabolism , Procollagen/physiology , Animals , Biopolymers , Breast Neoplasms/pathology , Humans , Procollagen/chemistry , Rats , Tumor Cells, Cultured
6.
Mutagenesis ; 17(1): 73-7, 2002 Jan.
Article in English | MEDLINE | ID: mdl-11752237

ABSTRACT

No single biomarker can predict the risk for malignant transformation of precancerous lesions of the head and neck. Micronucleus frequency, nuclear p53 accumulation and mitotic index were determined in proliferating basal cells using paraffin-embedded specimens from normal, dysplastic and malignant tissues. p53 accumulation was detected by immunohistochemistry using pAb 1081 and pAb 240 antibodies. Micronuclei were scored in the same cell population and classified for the presence/ absence of p53 accumulation in the main nucleus. Fifty-three carcinomas and 15 precancerous lesions were studied. Both micronuclei and p53 accumulation were found in precancerous lesions, suggesting that they are early events in head and neck squamous cell carcinoma progression. The two biomarkers were not related to each other: indeed, micronucleus frequency was higher in p53-negative than in p53-positive cells. Three patients with precancerous lesions later developed carcinomas; all three cases showed high frequencies of both micronuclei and cells accumulating p53 protein.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Squamous Cell/genetics , Cell Transformation, Neoplastic/genetics , Head and Neck Neoplasms/genetics , Micronucleus Tests , Neoplasm Proteins/analysis , Precancerous Conditions/genetics , Skin Diseases/genetics , Skin Neoplasms/genetics , Tumor Suppressor Protein p53/analysis , Biomarkers , Carcinoma, Squamous Cell/pathology , Disease Progression , Fibroblasts/chemistry , Fibroblasts/ultrastructure , G1 Phase , Head and Neck Neoplasms/pathology , Immunoenzyme Techniques , Mitotic Index , Precancerous Conditions/pathology , Skin Diseases/pathology , Skin Neoplasms/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...